f11photo / Shutterstock.com
11 August 2025NewsAmericasMarisa Woutersen

Harvard’s patent portfolio at risk as Trump turns up the pressure

Administration targets university’s federally funded research | Commerce Secretary warns of patent seizure under Bayh-Dole Act | Harvard given deadline to provide list of federally funded patents | Uncertainty continues across universities amid broader research cuts.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.
Generics
18 February 2024   While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Big Pharma
19 December 2023   The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation.

More on this story

Americas
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.
Generics
18 February 2024   While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Big Pharma
19 December 2023   The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation.

More on this story

Americas
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.
Generics
18 February 2024   While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Big Pharma
19 December 2023   The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation.